Literature DB >> 27458138

Hypoxia-Driven Mechanism of Vemurafenib Resistance in Melanoma.

Yong Qin1, Jason Roszik1, Chandrani Chattopadhyay1, Yuuri Hashimoto1, Chengwen Liu1, Zachary A Cooper1, Jennifer A Wargo1, Patrick Hwu1, Suhendan Ekmekcioglu1, Elizabeth A Grimm2.   

Abstract

Melanoma is molecularly and structurally heterogeneous, with some tumor cells existing under hypoxic conditions. Our cell growth assays showed that under controlled hypoxic conditions, BRAF(V600E) melanoma cells rapidly became resistant to vemurafenib. By employing both a three-dimensional (3D) spheroid model and a two-dimensional (2D) hypoxic culture system to model hypoxia in vivo, we identified upregulation of HGF/MET signaling as a major mechanism associated with vemurafenib resistance as compared with 2D standard tissue culture in ambient air. We further confirmed that the upregulation of HGF/MET signaling was evident in drug-resistant melanoma patient tissues and mouse xenografts. Pharmacologic inhibition of the c-Met/Akt pathway restored the sensitivity of melanoma spheroids or 2D hypoxic cultures to vemurafenib. Mol Cancer Ther; 15(10); 2442-54. ©2016 AACR. ©2016 American Association for Cancer Research.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 27458138      PMCID: PMC5079683          DOI: 10.1158/1535-7163.MCT-15-0963

Source DB:  PubMed          Journal:  Mol Cancer Ther        ISSN: 1535-7163            Impact factor:   6.261


  48 in total

1.  Improved overall survival in melanoma with combined dabrafenib and trametinib.

Authors:  Caroline Robert; Boguslawa Karaszewska; Jacob Schachter; Piotr Rutkowski; Andrzej Mackiewicz; Daniil Stroiakovski; Michael Lichinitser; Reinhard Dummer; Florent Grange; Laurent Mortier; Vanna Chiarion-Sileni; Kamil Drucis; Ivana Krajsova; Axel Hauschild; Paul Lorigan; Pascal Wolter; Georgina V Long; Keith Flaherty; Paul Nathan; Antoni Ribas; Anne-Marie Martin; Peng Sun; Wendy Crist; Jeff Legos; Stephen D Rubin; Shonda M Little; Dirk Schadendorf
Journal:  N Engl J Med       Date:  2014-11-16       Impact factor: 91.245

Review 2.  Hypoxia in cancer: significance and impact on clinical outcome.

Authors:  Peter Vaupel; Arnulf Mayer
Journal:  Cancer Metastasis Rev       Date:  2007-06       Impact factor: 9.264

3.  Impact of MET expression on outcome in BRAF(V600E/K) advanced melanoma.

Authors:  Adrian M Jubb; Antoni Ribas; Jeffrey A Sosman; Grant A McArthur; Yibing Yan; Sandra Rost; Sherry Zhao; Hartmut Koeppen
Journal:  Histopathology       Date:  2013-06-26       Impact factor: 5.087

Review 4.  Hypoxia, therapeutic resistance, and sphingosine 1-phosphate.

Authors:  Olivier Cuvillier; Isabelle Ader; Pierre Bouquerel; Leyre Brizuela; Cécile Gstalder; Bernard Malavaud
Journal:  Adv Cancer Res       Date:  2013       Impact factor: 6.242

Review 5.  Hypoxia, lactate accumulation, and acidosis: siblings or accomplices driving tumor progression and resistance to therapy?

Authors:  Arnulf Mayer; Peter Vaupel
Journal:  Adv Exp Med Biol       Date:  2013       Impact factor: 2.622

6.  Association of activated c-Met with NRAS-mutated human melanomas.

Authors:  Chandrani Chattopadhyay; Julie A Ellerhorst; Suhendan Ekmekcioglu; Victoria R Greene; Michael A Davies; Elizabeth A Grimm
Journal:  Int J Cancer       Date:  2012-01-11       Impact factor: 7.396

Review 7.  Tumor stroma: a complexity dictated by the hypoxic tumor microenvironment.

Authors:  A Casazza; G Di Conza; M Wenes; V Finisguerra; S Deschoemaeker; M Mazzone
Journal:  Oncogene       Date:  2013-04-22       Impact factor: 9.867

8.  Stabilization of hepatocyte growth factor mRNA by hypoxia-inducible factor 1.

Authors:  Sheng-Hua Chu; Dong-Fu Feng; Yan-Bin Ma; Zhi-An Zhu; Hong Zhang; Jian-Hua Qiu
Journal:  Mol Biol Rep       Date:  2008-11-02       Impact factor: 2.316

9.  Ribophorin II regulates breast tumor initiation and metastasis through the functional suppression of GSK3β.

Authors:  Ryou-u Takahashi; Fumitaka Takeshita; Kimi Honma; Masaya Ono; Kikuya Kato; Takahiro Ochiya
Journal:  Sci Rep       Date:  2013       Impact factor: 4.379

10.  RAF inhibitor resistance is mediated by dimerization of aberrantly spliced BRAF(V600E).

Authors:  Poulikos I Poulikakos; Yogindra Persaud; Manickam Janakiraman; Xiangju Kong; Charles Ng; Gatien Moriceau; Hubing Shi; Mohammad Atefi; Bjoern Titz; May Tal Gabay; Maayan Salton; Kimberly B Dahlman; Madhavi Tadi; Jennifer A Wargo; Keith T Flaherty; Mark C Kelley; Tom Misteli; Paul B Chapman; Jeffrey A Sosman; Thomas G Graeber; Antoni Ribas; Roger S Lo; Neal Rosen; David B Solit
Journal:  Nature       Date:  2011-11-23       Impact factor: 49.962

View more
  20 in total

Review 1.  Modifiable Host Factors in Melanoma: Emerging Evidence for Obesity, Diet, Exercise, and the Microbiome.

Authors:  Allison Betof Warner; Jennifer L McQuade
Journal:  Curr Oncol Rep       Date:  2019-07-01       Impact factor: 5.075

2.  Mutant Evolution in Spatially Structured and Fragmented Expanding Populations.

Authors:  Dominik Wodarz; Natalia L Komarova
Journal:  Genetics       Date:  2020-07-13       Impact factor: 4.562

Review 3.  MET: roles in epithelial-mesenchymal transition and cancer stemness.

Authors:  Hye-Min Jeon; Jeongwu Lee
Journal:  Ann Transl Med       Date:  2017-01

4.  HO-1 Limits the Efficacy of Vemurafenib/PLX4032 in BRAFV600E Mutated Melanoma Cells Adapted to Physiological Normoxia or Hypoxia.

Authors:  Anna Lisa Furfaro; Giulia Loi; Caterina Ivaldo; Mario Passalacqua; Gabriella Pietra; Giovanni Enrico Mann; Mariapaola Nitti
Journal:  Antioxidants (Basel)       Date:  2022-06-14

5.  Harnessing the polyamine transport system to treat BRAF inhibitor-resistant melanoma.

Authors:  Eric T Alexander; Olivia El Naggar; Erin Fahey; Kelsey Mariner; Julia Donnelly; Katelyn Wolfgang; Otto Phanstiel; Susan K Gilmour
Journal:  Cancer Biol Ther       Date:  2021-02-18       Impact factor: 4.742

6.  Temporal Quantitative Proteomics Reveals Proteomic and Phosphoproteomic Alterations Associated with Adaptive Response to Hypoxia in Melanoma Cells.

Authors:  Keshava K Datta; Parthiban Periasamy; Sonali V Mohan; Rebekah Ziegman; Harsha Gowda
Journal:  Cancers (Basel)       Date:  2021-04-30       Impact factor: 6.639

7.  A Novel Polyamine-Targeted Therapy for BRAF Mutant Melanoma Tumors.

Authors:  Molly C Peters; Allyson Minton; Otto Phanstiel Iv; Susan K Gilmour
Journal:  Med Sci (Basel)       Date:  2018-01-05

8.  A tool for discovering drug sensitivity and gene expression associations in cancer cells.

Authors:  Yong Qin; Anthony P Conley; Elizabeth A Grimm; Jason Roszik
Journal:  PLoS One       Date:  2017-04-28       Impact factor: 3.240

Review 9.  The role of tumor microenvironment in resistance to anti-angiogenic therapy.

Authors:  Shaolin Ma; Sunila Pradeep; Wei Hu; Dikai Zhang; Robert Coleman; Anil Sood
Journal:  F1000Res       Date:  2018-03-15

10.  Bufalin induces DNA damage response under hypoxic condition in myeloma cells.

Authors:  Eri Fujii; Yuki Inada; Misaki Kakoki; Nao Nishimura; Shinya Endo; Shiho Fujiwara; Naoko Wada; Yawara Kawano; Yutaka Okuno; Toshiya Sugimoto; Hiroyuki Hata
Journal:  Oncol Lett       Date:  2018-02-21       Impact factor: 2.967

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.